TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05372354: An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinati

Sponsor: Bristol-Myers Squibb · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$4,555,320

Rescue Site Savings

+$3,023,790

Unlock Full NCT05372354 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05372354 Rescue Dossier →